Register for free to
view the full innovation profile.
A simple and intensive DNA vaccine that elicits robust humoral and cell-mediated immune response to the Zika virus NS1 protein.
About
We have developed a simple and intensive DNA vaccine that elicits robust humoral and cell-mediated immune response to the Zika virus NS1 protein. It is highly immunogenic and offers complete systemic protection from Zika in vaccinated mice. The vaccine protects and completely eliminates Zika virus in preclinical studies. We have modified the plasmid DNA vaccine to include a leader sequence upstream of the NS1 gene, resulting in secretion of NS1 from vaccine-transfected cells – similar to what happens with NS1 during natural Zika infection in humans. The immunogenic portion of the sequence elicits various responses including T-helper response, a cytotoxic-T-cell Response, and/or a B-cell response.
Key Benefits
• Complete protection against infection. • Synthesizes a specific antigen response. • Excellent safety profile • No risk of antibody dependent enhancement of infections. • No vector immunity: prime – boost. • Low reactogenicity (candidate for pregnant women). • No need for adjuvant. • Stable for transportation and storage. • Easy manufacturing process.
Applications
A vaccine that protects and eliminates Zika virus and has the potential to treat or reduce transmission of Zika virus infection and to block transmission of Zika in mosquitoes.